+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • ID: 3797452
  • Drug Pipelines
  • October 2018
  • Region: Global
  • 475 pages
  • Datamonitor Healthcare
Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cases. The disease occurs predominantly in older people, with a median age of diagnosis around 65 years, and has a slightly higher prevalence in men than in women. DLBCL is categorized as an aggressive form of NHL; after initial onset the cancer advances quickly and can be fatal if left untreated. However, prompt and suitable treatment can lead to cure in more than 50% of cases.

Recent events and opinion
  • CAR-T therapies will become the highest-selling class over the forecast period.
  • The author’s survey of 223 medical oncologists in the US, Japan, and five major EU markets elucidates prescribing trends in DLBCL.
  • Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
  • CAR-T therapies Yescarta and Kymriah, as well as Keytruda in PMBCL patients, represent a new era in DLBCL treatment.
  • Several novel mechanisms are in development for DLBCL, signaling a potentially segmented future treatment paradigm.
Note: Product cover images may vary from those shown
FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 09 October 2018)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Blincyto
Product Profile: Keytruda
Product Profile (Late Stage): Kinenza
Product Profil
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 09 October 2018)
Overview
Product Overview
Product Profile: Keytruda
Product Profile: Kymriah
Product Profile: Rituxan
Product Profile: Yescarta

PIPELINE: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 09 October 2018)
Overview
Clinical Pipeline Overview
Target Product Profile
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Blincyto
Product Profile (Late Stage): Imbruvica
Product Profile (Late Stage): Kinenza
Product Profile (Late Stage): Mor208
Product Profile (Late Stage): Revlimid
Product Profile (Late Stage): Lisocabtagene Maraleucel
Product Profile (Late Stage): Polatuzumab Vedotin
Product Profile (Late Stage): Selinexor
Product Profile (Late Stage): Ublituximab
Product Profile (Late Stage): Umbralisib

LIST OF FIGURES
Figure 1: DLBCL – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for DLBCL
Figure 3: Diffuse large B-cell lymphoma drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Diffuse large B-cell lymphoma drug sales across the US, Japan, and five major EU markets, by class, 2017–26
Figure 5: CAR-T therapy sales in diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by drug, 2017–26
Figure 6: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 7: Pipeline therapy sales in diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by drug, 2017–26
Figure 8: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, 2017–26
Figure 9: Sales of rituximab biosimilars and lenalidomide generics for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, 2017–26
Figure 10: Patient-based forecast methodology for diffuse large B-cell lymphoma
Figure 11: Price sources and calculations, by country
Figure 12: Bavencio for diffuse large B-cell lymphoma – SWOT analysis
Figure 13: The authors drug assessment summary for Bavencio in diffuse large B-cell lymphoma
Figure 14: The authors drug assessment summary for Bavencio in diffuse large B-cell lymphoma
Figure 15: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Blincyto for diffuse large B-cell lymphoma – SWOT analysis
Figure 17: The authors drug assessment summary for Blincyto in diffuse large B-cell lymphoma
Figure 18: The authors drug assessment summary for Blincyto in diffuse large B-cell lymphoma
Figure 19: Blincyto sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Keytruda for diffuse large B-cell lymphoma – SWOT analysis
Figure 21: The authors drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 22: The authors drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 23: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Kinenza for diffuse large B-cell lymphoma – SWOT analysis
Figure 25: The authors drug assessment summary for Kinenza in diffuse large B-cell lymphoma
Figure 26: The authors drug assessment summary for Kinenza in diffuse large B-cell lymphoma
Figure 27: Kinenza sales for diffuse large B-cell lymphoma in the US, 2017–26
Figure 28: Kymriah for diffuse large B-cell lymphoma – SWOT analysis
Figure 29: The authors drug assessment summary for Kymriah in diffuse large B-cell lymphoma
Figure 30: The authors drug assessment summary for Kymriah in diffuse large B-cell lymphoma
Figure 31: Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: MOR208 for diffuse large B-cell lymphoma – SWOT analysis
Figure 33: The authors drug assessment summary for MOR208 in diffuse large B-cell lymphoma
Figure 34: The authors drug assessment summary for MOR208 in diffuse large B-cell lymphoma
Figure 35: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26
Figure 36: Revlimid for diffuse large B-cell lymphoma – SWOT analysis
Figure 37: The authors drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 38: The authors drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 39: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 40: Rituxan for diffuse large B-cell lymphoma – SWOT analysis
Figure 41: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 42: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 43: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 44: Yescarta for diffuse large B-cell lymphoma – SWOT analysis
Figure 45: The authors drug assessment summary for Yescarta in diffuse large B-cell lymphoma
Figure 46: The authors drug assessment summary for Yescarta in diffuse large B-cell lymphoma
Figure 47: Yescarta sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 48: Lisocabtagene maraleucel for diffuse large B-cell lymphoma – SWOT analysis
Figure 49: The authors drug assessment summary for lisocabtagene maraleucel in diffuse large B-cell lymphoma
Figure 50: The authors drug assessment summary for lisocabtagene maraleucel in diffuse large B-cell lymphoma
Figure 51: Lisocabtagene maraleucel sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 52: Polatuzumab vedotin for diffuse large B-cell lymphoma – SWOT analysis
Figure 53: The authors drug assessment summary for polatuzumab vedotin in diffuse large B-cell lymphoma
Figure 54: The authors drug assessment summary for polatuzumab vedotin in diffuse large B-cell lymphoma
Figure 55: Polatuzumab vedotin sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 56: Selinexor for diffuse large B-cell lymphoma – SWOT analysis
Figure 57: The authors drug assessment summary for selinexor in diffuse large B-cell lymphoma
Figure 58: The authors drug assessment summary for selinexor in diffuse large B-cell lymphoma
Figure 59: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 60: Ublituximab for diffuse large B-cell lymphoma – SWOT analysis
Figure 61: The authors drug assessment summary for ublituximab in diffuse large B-cell lymphoma
Figure 62: The authors drug assessment summary for ublituximab in diffuse large B-cell lymphoma
Figure 63: Ublituximab sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26
Figure 64: Umbralisib for diffuse large B-cell lymphoma – SWOT analysis
Figure 65: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 66: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 67: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26
Figure 68: Proportion of DLBCL patients diagnosed at each stage of disease, by country (%)
Figure 69: Top three first-line induction therapy regimens prescribed for the treatment of Stage I–II DLBCL, by country
Figure 70: Top three first-line induction therapy regimens prescribed for the treatment of Stage III–IV DLBCL, by country
Figure 71: Top three consolidation therapies prescribed for the treatment of Stage I–II DLBCL, by country
Figure 72: Top three consolidation therapies prescribed for the treatment of Stage III–IV DLBCL, by country
Figure 73: Top three second-line therapy regimens prescribed for the treatment of Stage I–IV stem cell eligible DLBCL patients, by country
Figure 74: Top three second-line therapy regimens prescribed for the treatment of Stage I–IV DLBCL patients not eligible for stem cell transplantation, by country
Figure 75: Top three third-line therapy regimens prescribed to Stage I–IV DLBCL patients who have previously received a stem cell transplant, by country
Figure 76: Top three third line therapy regimens prescribed to Stage I-IV DLBCL patients who have not previously received a stem cell transplant, by country
Figure 77: Trends in incident cases of NHL in the US, Japan, and five major EU markets, 2017–37
Figure 78: Trends in incident cases of DLBCL in the US, Japan, and five major EU markets, 2017–37
Figure 79: Trends in incident cases of FL in the US, Japan, and five major EU markets, 2017–37
Figure 80: Trends in incident cases of MCL in the US, Japan, and five major EU markets, 2017–37
Figure 81: Keytruda for diffuse large B-cell lymphoma – SWOT analysis
Figure 82: The authors drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 83: The authors drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 84: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 85: Kymriah for diffuse large B-cell lymphoma – SWOT analysis
Figure 86: The authors drug assessment summary for Kymriah in diffuse large B-cell lymphoma
Figure 87: The authors drug assessment summary for Kymriah in diffuse large B-cell lymphoma
Figure 88: Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 89: Rituxan for diffuse large B-cell lymphoma – SWOT analysis
Figure 90: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 91: The authors drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 92: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 93: Yescarta for diffuse large B-cell lymphoma – SWOT analysis
Figure 94: The authors drug assessment summary for Yescarta in diffuse large B-cell lymphoma
Figure 95: The authors drug assessment summary for Yescarta in diffuse large B-cell lymphoma
Figure 96: Yescarta sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 97: Bavencio for diffuse large B-cell lymphoma – SWOT analysis
Figure 98: The authors drug assessment summary for Bavencio in diffuse large B-cell lymphoma
Figure 99: The authors drug assessment summary for Bavencio in diffuse large B-cell lymphoma
Figure 100: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 101: Blincyto for diffuse large B-cell lymphoma – SWOT analysis
Figure 102: The authors drug assessment summary for Blincyto in diffuse large B-cell lymphoma
Figure 103: The authors drug assessment summary for Blincyto in diffuse large B-cell lymphoma
Figure 104: Blincyto sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 105: Imbruvica for diffuse large B-cell lymphoma – SWOT analysis
Figure 106: The authors drug assessment summary for Imbruvica in diffuse large B-cell lymphoma
Figure 107: The authors drug assessment summary for Imbruvica in diffuse large B-cell lymphoma
Figure 108: Kinenza for diffuse large B-cell lymphoma – SWOT analysis
Figure 109: The authors drug assessment summary for Kinenza in diffuse large B-cell lymphoma
Figure 110: The authors drug assessment summary for Kinenza in diffuse large B-cell lymphoma
Figure 111: Kinenza sales for diffuse large B-cell lymphoma in the US, 2017–26
Figure 112: MOR208 for diffuse large B-cell lymphoma – SWOT analysis
Figure 113: The authors drug assessment summary for MOR208 in diffuse large B-cell lymphoma
Figure 114: The authors drug assessment summary for MOR208 in diffuse large B-cell lymphoma
Figure 115: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26
Figure 116: Revlimid for diffuse large B-cell lymphoma – SWOT analysis
Figure 117: The authors drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 118: The authors drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 119: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 120: Lisocabtagene maraleucel for diffuse large B-cell lymphoma – SWOT analysis
Figure 121: The authors drug assessment summary for lisocabtagene maraleucel in diffuse large B-cell lymphoma
Figure 122: The authors drug assessment summary for lisocabtagene maraleucel in diffuse large B-cell lymphoma
Figure 123: Lisocabtagene maraleucel sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 124: Polatuzumab vedotin for diffuse large B-cell lymphoma – SWOT analysis
Figure 125: The authors drug assessment summary for polatuzumab vedotin in diffuse large B-cell lymphoma
Figure 126: The authors drug assessment summary for polatuzumab vedotin in diffuse large B-cell lymphoma
Figure 127: Polatuzumab vedotin sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 128: Selinexor for diffuse large B-cell lymphoma – SWOT analysis
Figure 129: The authors drug assessment summary for selinexor in diffuse large B-cell lymphoma
Figure 130: The authors drug assessment summary for selinexor in diffuse large B-cell lymphoma
Figure 131: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 132: Ublituximab for diffuse large B-cell lymphoma – SWOT analysis
Figure 133: The authors drug assessment summary for ublituximab in diffuse large B-cell lymphoma
Figure 134: The authors drug assessment summary for ublituximab in diffuse large B-cell lymphoma
Figure 135: Ublituximab sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26
Figure 136: Umbralisib for diffuse large B-cell lymphoma – SWOT analysis
Figure 137: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 138: The authors drug assessment summary for umbralisib in diffuse large B-cell lymphoma
Figure 139: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Diffuse large B-cell lymphoma drug sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Diffuse large B-cell lymphoma drug sales across the US, Japan, and five major EU markets, by class ($m), 2017–26
Table 3: CAR-T therapy sales in diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by drug ($m), 2017–26
Table 4: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Pipeline therapy sales in diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by drug ($m), 2017–26
Table 6: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 7: Sales of rituximab biosimilars and lenalidomide generics for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets ($m), 2017–26
Table 8: Exchange rates used for calculating prices
Table 9: Medical hematologists and hemato-oncologists surveyed for the DLBCL primary research study, 2016
Table 10: Bavencio drug profile
Table 11: Bavencio ongoing pivotal trial in diffuse large B-cell lymphoma
Table 12: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Blincyto drug profile
Table 14: Blincyto ongoing pivotal trial in diffuse large B-cell lymphoma
Table 15: Blincyto sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 16: Keytruda drug profile
Table 17: Keytruda pivotal trial data in diffuse large B-cell lymphoma
Table 18: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 19: Kinenza drug profile
Table 20: Kinenza pivotal trial data in diffuse large B-cell lymphoma
Table 21: Kinenza ongoing pivotal trial in diffuse large B-cell lymphoma
Table 22: Kinenza sales for diffuse large B-cell lymphoma in the US ($m), 2017–26
Table 23: Kymriah drug profile
Table 24: Kymriah pivotal trial data in diffuse large B-cell lymphoma
Table 25: Kymriah early-phase trial data in diffuse large B-cell lymphoma
Table 26: Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 27: MOR208 drug profile
Table 28: MOR208 ongoing pivotal trial in diffuse large B-cell lymphoma
Table 29: Early-phase data for MOR208 in diffuse large B-cell lymphoma
Table 30: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 31: Revlimid drug profile
Table 32: Revlimid ongoing pivotal trial in diffuse large B-cell lymphoma
Table 33: Early-phase data for Revlimid in diffuse large B-cell lymphoma
Table 34: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 35: Rituxan drug profile
Table 36: Rituxan pivotal trial data in diffuse large B-cell lymphoma
Table 37: Rituxan Phase III data in diffuse large B-cell lymphoma
Table 38: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 39: Yescarta drug profile
Table 40: Yescarta pivotal trial data in diffuse large B-cell lymphoma
Table 41: Yescarta ongoing late-phase trial in diffuse large B-cell lymphoma
Table 42: Yescarta sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 43: Lisocabtagene maraleucel drug profile
Table 44: Lisocabtagene maraleucel pivotal trial data in diffuse large B-cell lymphoma
Table 45: Lisocabtagene maraleucel ongoing pivotal trial in diffuse large B-cell lymphoma
Table 46: Lisocabtagene maraleucel sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 47: Polatuzumab vedotin drug profile
Table 48: Polatuzumab vedotin ongoing pivotal trial in diffuse large B-cell lymphoma
Table 49: Early-phase data for polatuzumab vedotin in diffuse large B-cell lymphoma
Table 50: Polatuzumab vedotin sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 51: Selinexor drug profile
Table 52: Selinexor pivotal trial data in diffuse large B-cell lymphoma
Table 53: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 54: Ublituximab drug profile
Table 55: Ublituximab ongoing pivotal trial in diffuse large B-cell lymphoma
Table 56: Ublituximab sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 57: Umbralisib drug profile
Table 58: Umbralisib ongoing pivotal trial in diffuse large B-cell lymphoma
Table 59: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 60: Medical hematologists and hemato-oncologists surveyed for the DLBCL primary research study, 2016
Table 61: Non-Hodgkin’s lymphoma five-year survival rates, by stage of diagnosis, 2008–14
Table 62: Immunophenotypic diagnosis of DLBCL
Table 63: International prognostic Index for DLBCL
Table 64: Risk groups in DLBCL classified by the international prognostic index
Table 65: Ann Arbor staging used in lymphoma
Table 66: Targeted drugs for the treatment of DLBCL
Table 67: Main chemotherapies for the treatment of DLBCL
Table 68: Cancer registry databases used as a source of NHL, DLBCL, FL, and MCL incidence data, by country
Table 69: Ann Arbor classification system
Table 70: Incident cases of NHL in the US, Japan, and five major EU markets, 2017–37
Table 71: Incident cases of DLBCL in the US, Japan, and five major EU markets, 2017–37
Table 72: Incident cases of FL in the US, Japan, and five major EU markets, 2017–37
Table 73: Incident cases of MCL in the US, Japan, and five major EU markets, 2017–37
Table 74: Profiled key marketed drugs for diffuse large B-cell lymphoma
Table 75: Keytruda drug profile
Table 76: Keytruda pivotal trial data in diffuse large B-cell lymphoma
Table 77: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 78: Kymriah drug profile
Table 79: Kymriah pivotal trial data in diffuse large B-cell lymphoma
Table 80: Kymriah early-phase trial data in diffuse large B-cell lymphoma
Table 81: Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 82: Rituxan drug profile
Table 83: Rituxan pivotal trial data in diffuse large B-cell lymphoma
Table 84: Rituxan Phase III data in diffuse large B-cell lymphoma
Table 85: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 86: Yescarta drug profile
Table 87: Yescarta pivotal trial data in diffuse large B-cell lymphoma
Table 88: Yescarta ongoing late-phase trial in diffuse large B-cell lymphoma
Table 89: Yescarta sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 90: Profiled pipeline products in development for diffuse large B-cell lymphoma
Table 91: Rituxan drug profile
Table 92: Rituxan pivotal trial data in diffuse large B-cell lymphoma
Table 93: Rituxan Phase III data in diffuse large B-cell lymphoma
Table 94: Bavencio drug profile
Table 95: Bavencio ongoing pivotal trial in diffuse large B-cell lymphoma
Table 96: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 97: Blincyto drug profile
Table 98: Blincyto ongoing pivotal trial in diffuse large B-cell lymphoma
Table 99: Blincyto sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 100: Imbruvica drug profile
Table 101: Imbruvica pivotal trial data in diffuse large B-cell lymphoma
Table 102: Early-phase data for Imbruvica in diffuse large B-cell lymphoma
Table 103: Kinenza drug profile
Table 104: Kinenza pivotal trial data in diffuse large B-cell lymphoma
Table 105: Kinenza ongoing pivotal trial in diffuse large B-cell lymphoma
Table 106: Kinenza sales for diffuse large B-cell lymphoma in the US ($m), 2017–26
Table 107: MOR208 drug profile
Table 108: MOR208 ongoing pivotal trial in diffuse large B-cell lymphoma
Table 109: Early-phase data for MOR208 in diffuse large B-cell lymphoma
Table 110: MOR208 sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 111: Revlimid drug profile
Table 112: Revlimid ongoing pivotal trial in diffuse large B-cell lymphoma
Table 113: Early-phase data for Revlimid in diffuse large B-cell lymphoma
Table 114: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 115: Lisocabtagene maraleucel drug profile
Table 116: Lisocabtagene maraleucel pivotal trial data in diffuse large B-cell lymphoma
Table 117: Lisocabtagene maraleucel ongoing pivotal trial in diffuse large B-cell lymphoma
Table 118: Lisocabtagene maraleucel sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 119: Polatuzumab vedotin drug profile
Table 120: Polatuzumab vedotin ongoing pivotal trial in diffuse large B-cell lymphoma
Table 121: Early-phase data for polatuzumab vedotin in diffuse large B-cell lymphoma
Table 122: Polatuzumab vedotin sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 123: Selinexor drug profile
Table 124: Selinexor pivotal trial data in diffuse large B-cell lymphoma
Table 125: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 126: Ublituximab drug profile
Table 127: Ublituximab ongoing pivotal trial in diffuse large B-cell lymphoma
Table 128: Ublituximab sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 129: Umbralisib drug profile
Table 130: Umbralisib ongoing pivotal trial in diffuse large B-cell lymphoma
Table 131: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
Adroll
adroll